Under Inclusions: #4: "....Subjects must be untre
Post# of 155478
(Total Views: 570)
Posted On: 07/04/2025 1:22:03 PM
Under Inclusions:
#4: "....Subjects must be untreated or naïve to chemotherapy and/or checkpoint inhibitors exposure in metastatic setting..."
Outcome Measure:
Phase II: Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1)
Outcome Measure:
Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.
NCT03838367
Study Start: 4/2019
Completion: 7/2022
Follow-up : 2 years / death
** Amarex settlement 7/2024 **
___
The ICI timeline:
2022 SK video said contracted for LL/ICI synergies.
Cytodyn website video, references ICI & T-cells.
Sept. 2024 Shareholder Letter:
References ICI studies
Cytodyn May 13th, 2025:
" Survival observations in mTNBC patients correlated with increased PD-L1 expression
Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” "
"....and found that leronlimab treatment correlated with increased expression of an immune cell protein or “checkpoint inhibitor” known as programmed death-ligand 1 (“PD-L1”) on patient’s circulating tumor cells (“CTCs”)."
___
Many ICI references over the years.
Minus using one simple word related to Leronlimab:
Upregulating.
We are building a 100% new treatment industry:
LL + ICI
LL-PLS + ICI
WOW !!
https://investorshangout.com/post/view?id=6774325
#4: "....Subjects must be untreated or naïve to chemotherapy and/or checkpoint inhibitors exposure in metastatic setting..."
Outcome Measure:
Phase II: Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1)
Outcome Measure:
Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.
NCT03838367
Study Start: 4/2019
Completion: 7/2022
Follow-up : 2 years / death
** Amarex settlement 7/2024 **
___
The ICI timeline:
2022 SK video said contracted for LL/ICI synergies.
Cytodyn website video, references ICI & T-cells.
Sept. 2024 Shareholder Letter:
References ICI studies
Cytodyn May 13th, 2025:
" Survival observations in mTNBC patients correlated with increased PD-L1 expression
Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” "
"....and found that leronlimab treatment correlated with increased expression of an immune cell protein or “checkpoint inhibitor” known as programmed death-ligand 1 (“PD-L1”) on patient’s circulating tumor cells (“CTCs”)."
___
Many ICI references over the years.
Minus using one simple word related to Leronlimab:
Upregulating.
We are building a 100% new treatment industry:
LL + ICI
LL-PLS + ICI
WOW !!
https://investorshangout.com/post/view?id=6774325
(2)
(0)